about
Spatial and temporal characteristics of normal and perturbed vesicle transportSynthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.In vivo effects of a GPR30 antagonistHER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinomaPET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.Functional differences between neurotransmitter binding sites of muscle acetylcholine receptors.In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers86Y based PET radiopharmaceuticals: radiochemistry and biological applicationsThe intrinsic energy of the gating isomerization of a neuromuscular acetylcholine receptor channel.Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.Structural correlates of affinity in fetal versus adult endplate nicotinic receptorsLinkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates.Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.PET imaging to monitor cancer therapy.Isolation and (111)In-Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model.Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3.
P50
Q27332721-A100FE93-B67F-4C1D-A9D9-761F6FEB9E33Q28484415-FFA9E13C-1748-4EB3-81FA-7172A1C75A06Q31121875-8223BD9A-5842-4B2B-BB33-460F3674797CQ33661325-C7C3F813-714B-4055-86E4-60F521114245Q33828472-A4F25465-119E-40F5-8531-2A44CD9E91FCQ33862523-4619A31D-BA89-404D-8B54-226E36DDF573Q33939881-D566E768-C7C4-4F42-9E44-0F55A038DF70Q33943630-D682BEC4-E07B-4134-8E28-41F0B784BB11Q34126406-9BF26E0C-16BF-4FBB-B2F8-B141EE7FA0B1Q34518285-D416ACF7-9B94-4CA6-89AE-4D0776C1BA8DQ34708761-84ED9974-49C5-43CA-A0D8-AF0CD1234706Q35162293-07EEFD19-2A9B-4BD3-A2E0-FBBD239ABBD0Q35250409-4EA6AA71-BFBB-4F45-9763-D05BA39E555EQ35931875-606B4644-B813-4FA8-8282-9C81A7EA1F7BQ36096813-6E45A979-561E-4ED0-B2EB-E341F91D806CQ36710964-31005669-2D85-437C-8CC4-03179257D4C6Q36731191-37FF55C8-B697-479B-ABC3-5B5C2D66C74EQ36835679-9113D338-0AA0-4D35-9DE5-0CE3565509DAQ36999515-CAB6CB23-148B-45F4-A962-6942A313AD9DQ37698959-A25F0F05-BEAE-48D5-9163-455FFDD2E391Q38174117-2B291501-267E-4E1E-9C6E-41AFB9780C15Q38787413-0C7BBD2D-2838-4B7C-B65D-F01CD77E2B12Q39019835-F0397B09-42D8-48EF-A946-D5CD7E58EA76Q39416858-DC6215C1-88AE-40F3-88D0-AFFA27A968C7Q39954213-C62DA6B7-107B-4A38-86C0-404A9C6CA21BQ40169970-4063A7FD-BB5B-471A-B1CD-BE6F179DEF3EQ46934969-CDC183FA-791C-4317-B768-B080A8578AA3Q52987292-D3424301-C7E0-4B0D-9288-91AE04EC19CF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tapan K. Nayak
@ast
Tapan K. Nayak
@en
Tapan K. Nayak
@es
Tapan K. Nayak
@nl
Tapan K. Nayak
@sl
type
label
Tapan K. Nayak
@ast
Tapan K. Nayak
@en
Tapan K. Nayak
@es
Tapan K. Nayak
@nl
Tapan K. Nayak
@sl
prefLabel
Tapan K. Nayak
@ast
Tapan K. Nayak
@en
Tapan K. Nayak
@es
Tapan K. Nayak
@nl
Tapan K. Nayak
@sl
P106
P1153
35410103300
P31
P496
0000-0002-3706-6092